Patient-Reported Outcomes in Digital Patient Support Programmes: Building Real-World Evidence in Saudi Arabia
How structured PROMs turn a digital patient support programme into a real-world evidence source, with the consent design PDPL requires.
Key takeaways
- Patient support programmes provide a cost-effective infrastructure to generate real-world evidence through enrolment and ongoing patient contact.
- Using PROMs data for research requires explicit informed consent, kept completely separate from programme participation consent under Saudi PDPL regulations.
- PROMs collected in digital programmes must use validated, Arabic-appropriate instruments, while routing any reported adverse events to a separate pharmacovigilance pathway.
Reviewed by the CareSync Medical Team · Last reviewed
On this page
A digital patient support programme already collects a stream of information: enrolment data, adherence contact, side-effect alerts and patient questions. Adding structured patient-reported outcome measures (PROMs) turns that stream into something pharmaceutical teams, providers and payers can use for a second purpose: real-world evidence that complements clinical trial data and shows how treatment performs in everyday Saudi practice.
Key takeaways
- Patient support programmes are an established source of real-world evidence globally. An industry analysis of real-world evidence generated from patient support programmes identifies patient-reported outcomes as one of the core categories of information collected through enrolment and ongoing contact.
- Studying PSP data is efficient. The same analysis describes collecting this programme data as a cost-effective way to generate real-world evidence, because the contact infrastructure already exists.
- Consent must be separate and explicit. Using PROMs data for research requires its own informed consent, separate from consent to participate in the programme, in line with Personal Data Protection Law requirements for sensitive data.
- Validated instruments still apply. PROMs collection inside a PSP must use the same validated, Arabic-appropriate instruments used in any other clinical setting — not an informal substitute.
- Adherence and outcomes data reinforce each other. International studies of patient support programmes have linked structured support, including outcomes tracking, to measurable differences in persistence and adherence.
What PROMs data can a PSP realistically collect?
| Data type | Example | Usual use |
|---|---|---|
| Adherence and persistence | Refill timing, missed-dose reports | Programme effectiveness, early non-adherence signals |
| Patient-reported outcomes | Validated quality-of-life or symptom instruments | Real-world evidence, understanding treatment experience |
| Patient-reported experience | Satisfaction with support, ease of access | Programme design and service improvement |
| Adverse event alerts | Side effects or complaints reported in contact | Pharmacovigilance, routed separately from research use |
How does PROMs data inside a PSP differ from research consent?
| Consent purpose | What it covers | What it does not cover |
|---|---|---|
| Programme participation | Enrolment, support delivery and adherence contact | Use of data for research |
| Safety reporting | Monitoring and escalating adverse events | Use of data for research |
| Research use | Separate, explicit consent to use PROMs or other data in real-world evidence studies | Cannot be inferred from participation consent alone |
This reflects the consent design principle in the CareSync guide to patient enrolment and PDPL consent in digital patient support programmes: each purpose has its own specific agreement.
A five-step plan for pharmaceutical teams adding PROMs to a PSP
- Define the evidence question first. Decide what you want to learn before choosing an instrument, so collection is purposeful rather than exploratory.
- Choose a validated, Arabic-appropriate instrument. Use the same standards described in the CareSync PROMs implementation guide, including proper translation and licensing.
- Design a separate, explicit research consent. Keep it distinct from programme participation consent and safety reporting consent.
- Keep pharmacovigilance and research pathways separate. A side effect mentioned in a PROM response may also be a reportable adverse event; define both routes clearly.
- Plan the analysis before launch. Agree who analyses the data, under what governance, and how results will be used or published.
How CareSync PSP Connect helps
CareSync PSP Connect is the version of the CareSync white-label digital health ecosystem designed for pharmaceutical patient support programmes. It is designed to support PROMs questionnaire delivery alongside enrolment, consent capture with versioning and timestamps, and adverse event flagging with an audit trail. Programmes run through the treating provider's own branded channel. CareSync does not conduct or own research studies; study design, consent wording and analysis remain the responsibility of the sponsor, the provider and their research partners.
Frequently asked questions
Can PSP data be used for real-world evidence in Saudi Arabia? It can, when patients give separate, informed consent for research use and the programme is designed for that purpose from the start.
Does real-world evidence from PSPs replace clinical trial data? No. It complements trial data by showing how treatment performs in everyday use, with different strengths and limitations from controlled trials.
Do PROMs collected in a PSP need the same validation as those used in hospitals? Yes. An instrument's validity does not change with where it is delivered; informal or improvised questions do not meet the same standard of evidence.
How is a PROM response handled if it mentions a side effect? It must be flagged and routed through the programme's pharmacovigilance pathway, separate from its use in outcomes or research analysis.
Who owns PROMs data collected in a PSP? That depends on the programme contracts between the sponsor, the provider and the platform vendor, and it should be defined in writing.
Can PROMs data from a PSP be published? It can, subject to the consent given, data protection requirements, research governance and the sponsor's publication policies.
Evidence that reflects everyday practice
A digital patient support programme that collects PROMs with sound consent and validated instruments becomes more than a support channel. It becomes a source of real-world evidence grounded in how Saudi patients actually experience treatment.
Designing a patient support programme with outcomes measurement? Book a demo with CareSync.
About CareSync
Prepared by the CareSync Medical Team. This article is educational, not medical advice or a substitute for clinical, legal or regulatory review. Research findings are source-specific, not measured CareSync outcomes.